Excluding Orphan Drugs from the 340B Drug Discount Program:  the Impact on 18 Critical Access Hospitals by Wallack, Madeline Carpinelli & Sorensen, Todd
Volume 3 | Number 1 Article 70
2012
Excluding Orphan Drugs from the 340B Drug
Discount Program: the Impact on 18 Critical
Access Hospitals
Madeline Carpinelli Wallack
Todd Sorensen
soren042@umn.edu
Follow this and additional works at: http://pubs.lib.umn.edu/innovations
INNOVATIONS in pharmacy is published by the University of Minnesota Libraries Publishing.
Recommended Citation
Wallack MC, Sorensen T. Excluding Orphan Drugs from the 340B Drug Discount Program: the Impact on 18 Critical Access
Hospitals. Inov Pharm. 2012;3(1): Article 70. http://pubs.lib.umn.edu/innovations/vol3/iss1/7
Original Research POLICY 
 
http://z.umn.edu/INNOVATIONS                           2012, Vol. 3, No. 1, Article 70                       INNOVATIONS in pharmacy   1 
 
Excluding Orphan Drugs from the 340B Drug Discount Program:  the Impact on 18 Critical Access Hospitals 
Madeline Carpinelli Wallack
1 
and Todd Sorensen, PharmD
2 
1 
Research Fellow, PRIME Institute and PhD candidate, Social & Administrative Pharmacy, University of Minnesota, Minneapolis, MN 
and 
2
Department of Pharmaceutical Health Care, University of Minnesota, Minneapolis, MN 
 
Key Words:  340B Drug Discount Program, Critical Access Hospitals, Orphan Drugs 
 
Acknowledgements:  We gratefully acknowledge Charles Cooper, 340B Program Manager, Fairview Hospital, with whom we 
collaborated on this project.  We also appreciate the editorial feedback on earlier versions of this paper from Suzanne Herzog, Rx|X 
LLC, Shelleaha Nippoldt, University of Minnesota, and Francis Carpinelli, Professor Emeritus, Benedictine College.  
 
Abstract 
Purpose: The 340B Drug Pricing Program is a federal program designed to reduce the amount that safety net providers spend on 
outpatient drugs. The Patient Protection and Affordable Health Care Act of 2010 extended eligibility for 340B to critical access 
hospitals (CAHs) for all drugs except those designated as “orphan.”  Because this policy is unprecedented, this study quantifies the 
gross financial impact that this exemption has on a group of CAHs. Methods: Drug spending for 2010 from 18 CAHs in Minnesota and 
Wisconsin are reviewed to identify the prevalence of orphan drug purchases and to calculate the price differentials between the 340B 
price and the hospitals’ current cost. Results: The 18 CAHs’ purchases of orphan drugs comprise an average of 44% of the total 
annual drug budgets, but only 5% of units purchased, thus representing a very high proportion of their expenditures. In the 
aggregate, the 18 hospitals would have saved $3.1 million ($171,000 average per hospital) had purchases of drugs with orphan 
designations been made at the 340B price.  Because CAH claims for Medicare are reimbursed on a cost-basis, the Federal 
government is losing an opportunity for savings. Conclusion: The high prevalence of orphan drug use and considerable potential for 
cost reduction through the 340B program demonstrate the loss of benefit to the hospitals, Federal government and the states.  
 
 
Introduction 
The high cost of prescription drugs is now and has been a 
major obstacle in containing health care costs, particularly 
when it comes to containing the amount public insurance 
pays. One program designed to help lower drug spending is 
the federal 340B Drug Pricing Program (340B program), which 
has been administered by the Health Resources and Services 
Administration’s Office of Pharmacy Affairs (HRSA/OPA) since 
1992.  The 340B program requires that pharmaceutical 
manufacturers provide outpatient drugs at or below 
statutorily defined prices, known as 340B ceiling prices, to 
specified grantees and hospitals.
1
 In essence, the discount 
available through 340B reduces prescription drug costs for 
safety net providers that serve the indigent and majority of 
Medicare/Medicaid beneficiaries, such as community health 
centers and public hospitals.   
 
The Patient Protection and Affordable Care Act (ACA), 
enacted on March 23, 2010, expands the 340B program to 
four new entities, taking the total number of eligible entities  
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from 12 to 16.  The “ACA-eligible” entities, as OPA refers to 
them, include four categories of hospitals:  free-standing 
cancer hospitals, Critical Access Hospitals (CAHs), Rural 
Referral Centers (RRCs) and Sole Community Hospitals 
(SCHs).
2   
These entities are small-scale hospitals, with CAHs, 
RRCs and SCHs specifically serving rural communities.
  
 
 
Though full access to the 340B program should translate into 
heightened drug cost containment for these hospitals, a last-
minute amendment to the ACA adversely impacts the 
financial benefit that 340B is intended to provide.  One week 
following the passage of the ACA, language was added to 
exclude the 340B discount for drugs designated by the Food 
and Drug Administration (FDA) as “orphan drugs” to the ACA-
eligible entities, but entities previously eligible for the 340B 
program were not affected.
3
  Broadly speaking, orphan drugs 
are products that the FDA has designated as treatments for 
rare diseases.  Manufacturers of orphan products receive 
special incentives in exchange for the research and 
development invested to find treatment options.  However, 
orphan drugs are not used solely for rare diseases and are 
often among the most costly products on the market. As 
such, this exclusionary policy for the new entities translates 
into a significant missed opportunity for governmental 
savings.  
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Orphan Drugs 
The Orphan Drug Act of 1983 was enacted to provide 
incentives for manufacturers to develop drugs for rare 
diseases that affect a small portion of the population, which 
is defined by the Act as affecting fewer than 200,000 people.
4
  
Drugs that treat diseases affecting a larger portion of the 
population are also eligible under the Act if the costs of 
development and manufacturing are expected to exceed 
sales.  The Act allows companies to take a 50 percent tax 
credit on all clinical trial costs, exempts them from some FDA 
user fees, and precludes competitors from obtaining FDA 
approval for the same drug for seven years.
5 
  The intent of 
the Act is to foster the potential market for such drugs, which 
might not exist in the absence of such incentives due to the 
difficultly in recovering high development costs.
6
    
 
Under the Orphan program, the FDA may confer one of two 
classifications on a drug:  an “orphan designation” or 
“approved for orphan indication”.
7
   The process to receive 
orphan designation is fairly straightforward: manufacturers 
must show the FDA that the product‘s use will be for a rare 
condition.  Primary clinical trials are not necessary to receive 
this classification.  As of January 2012, the FDA has granted 
1,782 orphan designations.
8
   To be “approved for an orphan 
indication” the manufacturers undergo a more rigorous 
process, which includes establishing the safety and efficacy of 
the drug via clinical trials.  Products may obtain more than 
one approval for orphan indications.  To date, the FDA has 
granted 389 approvals for orphan indication.
9
   
 
The final interpretation of the ACA’s use of the term “orphan 
drugs” has yet to be decided, and the financial impact of the 
various scenarios has not been analyzed.  HRSA issued 
proposed regulations on May 20, 2011, which have not been 
finalized.
10
  These regulations call for the exclusion from the 
340B discount to be applied exclusively for its approved 
indication.  Pharmaceutical manufacturers opine that a drug 
that has orphan designation should be exempt regardless of 
how the drug is used.
11
 Additionally, legislation has been 
introduced that calls for a full repeal of the orphan 
exception.
12
  
 
Though the final policy for implementation of the exclusion 
has yet to be determined, the objective of this paper is to 
illustrate how the most conservative interpretation of the 
policy—a full exemption of all orphan products—has 
impacted a subset of the entities affected.  
 
Purpose 
To quantify the financial impact of the orphan drug exclusion 
policy in the 340B program for 18 critical access hospitals.  
 
Methods 
Selection of Entity Type for Review 
This study reviews the invoices for drug purchases from 18 
CAHs that participate in the Fairview Purchasing Network 
(FPN), a group purchasing cooperative operated by Fairview 
Health Systems in Minneapolis, MN.  Sixteen of the hospitals 
are located in Minnesota and 2 are located in Wisconsin.  This 
study elected to review CAHs because they represent the 
majority share of rural hospitals that are newly-eligible for 
340B.
13
 Moreover, of the new entity types, 77 percent of 
organizations that have enrolled since the August 1
st
, 2010 
start date for participation are CAHs.
14
  
 
Data Collection 
Invoice data for 2010 from the 18 CAHs was extracted, 
categorized and analyzed to identify purchases of drugs with 
orphan designations and to calculate the price difference 
between their current cost and the 340B discount for those 
drugs.   
 
The invoices were initially scanned to identify only 340B-
eligible purchases.  Line items that included products 
ineligible for 340B, such as vaccines, test strips and other 
supplies, were excluded.  The resulting list of eligible 
purchases made by the 18 hospitals was indexed against the 
FDA’s Orphan Drug Database to flag those drugs with an 
orphan designation.  This indexing resulted in the 
identification of 111 unique orphan products.   
 
 To calculate the price differences between the hospital’s 
current cost and the 340B price, this study utilized data 
maintained by FPN.
  
The current cost to the hospitals is based 
on Wholesale Acquisition Cost or as negotiated by Premier, 
their Group Purchasing Organization.  The 340B list price for 
the same timeframe was additionally provided through the 
FPN.  Comparisons were made only on line items where there 
was both a GPO and a 340B price. Prices that were “N/A” or 
“$0.00” were also not included in the analysis.  
The 340B program is for outpatient drugs only, yet CAHs 
purchasing drugs at the GPO price have not historically been 
required to split inventory between outpatient and inpatient 
settings.  In the absence of such readily-available data, the 
authors determined that imputing 100% outpatient use was 
reasonable for three reasons.  First, informal discussions with 
a number of the CAH pharmacy directors in this study and 
pharmacists within the FPN about the settings for which 
these orphan drugs are used confirmed that the vast majority 
of these products would be used 100% in an outpatient 
setting. More specifically, most of the drugs reviewed in this 
study are drugs that would be used in outpatient oncology 
clinics.  Second, CAHs, by definition, provide acute care versus 
ongoing treatment; as such, patients with rare conditions 
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would likely be referred to primary and specialty providers to 
receive more focused care.
13
 Third, in light of this uncertain 
policy environment, assuming 100% outpatient use of drugs 
with orphan designations permitted contemplation of the 
most conservative implementation scenario of the statute.  In 
other words, the findings reflect the maximum amount of lost 
savings available to CAHs if orphan drugs were fully-excluded 
from the 340B program.     
 
Result 
 In 2010, the 18 CAHs’ total drug purchases at the GPO price 
were $22.5 million.  The median annual drug expenditure by 
hospital was $1.1 million, with the range spanning $197,000 
to $3.5 million.  The hospitals’ expenditures on drugs with 
orphan designations were high, representing an aggregate 
44% of drug purchases (Table 1).  In sharp contrast, the 
aggregate quantity of orphan drugs purchased was only 5%.  
Due to the high costs of orphan drugs, these products 
represent an extremely high proportion of the 18 hospitals’ 
expenditures in relation to the number of units purchased.  A 
portion of this difference is explained by the fact that drugs 
with orphan designations are, on average, more expensive 
than those without.  For example, considering just the 4
th
 
quarter of 2010, the average GPO cost for a drug (by NDC) 
with orphan designation was $794.00 versus $94.00 for drugs 
without the designation.     
 
Based on the price differences between the 340B and GPO 
price for 2010, had the 18 CAHs’ purchases of orphan drugs 
been available at the 340B price, the savings would total $3.1 
million.  By hospital, this translates to an average annual 
orphan drug savings of $171,000, or 14% of the average 
annual total CAH drug budget.   
 
For the top 10 drugs with orphan designations purchased by 
the 18 hospitals, the difference between the 340B price and 
the GPO ranged from 12% to 48%, with a median difference 
of 31%.  As illustrated in Table 2, the top 10 drugs with 
orphan designations that demonstrated the highest potential 
annual savings from the 340B program for the 18 hospitals 
were led by Remicade®, Rituxan® and Herceptin®.  Of the 
$3.1 million in total savings projected for the 18 CAHs, these 
10 drugs represent $2.5 million, or 81% of the total calculated 
savings.     
 
In addition to the cost differences realized at the point of 
purchase, statutory provisions embedded within the 
calculation for the 340B price include protections against 
price increases over time.  Though the exact mechanics of the 
inflation protection mechanism are complex, simply put, 
when drug manufacturers raise prices in the commercial 
market faster than the rate of the Consumer Price Index-
Urban, a penalty goes into effect, thus reducing the 340B 
price for the eligible entities.   In addition to the difference in 
the upfront reduction in cost that the 340B program offers, 
purchasing drugs at the 340B price compared to the GPO 
price over 2010 results in savings over time.  Table 1 shows 
the opposite direction of the GPO price over the year 
compared to the 340B price for the 18 hospitals’ purchases 
for the top 5 drugs with orphan designation.  
 
Discussion 
The results show that the orphan exception for CAHs has a 
significantly negative financial impact on these hospitals.  
Expenditures on prescription drugs are a key concern across 
the entire health care system, particularly in light of rising 
pharmaceutical costs, the general state of the economy, the 
increasing age of the population, and growing use of costly 
specialty and infusion drugs, which are more likely to have 
orphan indications. As such, it is important to capitalize on 
the savings available at the 340B price for these drugs.  
 
Aside from the reduction in costs to these hospitals and the 
public insurance programs who reimburse them, the orphan 
drug exclusion elicits a number of larger topics for discussion.  
  
1. The Orphan Drug Exclusion Has Affected Participation in 
340B 
 A discount of between 25%-50% off current drug costs would 
go a long way in mitigating the financial, staffing and 
sustainability challenges unique to CAHs.
15
  Yet, according to 
340B advocacy organizations, the newly covered entities that 
the law intended to help are not signing up in large part due 
to the orphan exception.
16 
  Prior work on the 340B 
experience of the rural hospitals’ made eligible by the 2003 
Medicare Modernization Act revealed that one of the most 
important factors influencing participation was expected cost 
savings, so the exemption is likely influencing enrollment.
17
  
Even HRSA has acknowledged the possibility that the lack of 
access to 340B pricing on orphan drugs is dissuading 
enrollment, “we have heard during national conferences that 
may be the case.”
18 
  
 
Though a CAH should consider other variables, such as 
implementation and compliance costs, when calculating the 
net effect of participation in 340B, reservations about the 
potential for savings on non-orphan products will likely 
influence the decision to participate.  In the fall of 2010, the 
Safety Net Hospitals for Pharmaceutical Access and the 
National Rural Health Association partnered to advocate for a 
repeal of the orphan drug exemption for the new entity 
types.  The two organizations administered a survey to 140 
eligible facilities and found that 82 percent reported that the 
removal of the exclusion was “very important,” and that 
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expenditures on these drugs comprised a significant share of 
general drug budgets.
19
    
 
2. Decreased Access to the 340B Program for Savings Can 
Affect Patient Care  
Previous studies have found that the 340B discount produces 
savings that are used in a number of ways, such as serving 
more patients, offsetting the cost of uncompensated care for 
the uninsured or underinsured, and increasing the scope of 
services offered.
20
 A 2004 survey of 340B participants found 
that savings from the discount can “increase and/or improve 
services at the hospital, offset losses in other departments, 
reduce medication prices to the patient, and increase the 
quantity and/or variety of drugs available."
21
 In June 2011, 
the Safety Net Hospitals for Pharmaceutical Access (SNHPA) 
released a report on the value of the drug discount program 
to patients and hospitals.  The survey of over 600 member 
hospitals found that the program is critical to hospital 
operations; the savings from the program reduce costs to 
patients, and increase patient access to pharmacy services.
22 
 
In summary, reducing the potential savings available to these 
entities impacts their ability to provide these important 
services.   
 
3. Use of Drugs with Orphan Designation is not Limited to 
Rare Diseases 
The policy to exempt orphan drugs from the 340B program 
for these entities does not seem to consider the total use of 
the drug and its market reach.  Drugs with orphan 
designations often have more common applications, and the 
orphan indication may just be one of the many approved uses 
of the drug.  As a result, the total use of an orphan product 
can be considerably more widespread than imagined, 
reducing the notion of “rare” use.  In fact, 25 of the top 100 
products in the US market by sales in 2009 were orphan 
designated drugs.
23   
 
   
 
Orphan drugs, which include cancer treatments, blood 
products and other infused specialty medications, are among 
the most expensive products on the market and, 
consequently, often represent a significant share of a 
hospital’s pharmacy budget.  Through 2010, the largest 
clinical sub-category of drugs that have received orphan 
designation is oncology products.
24
 Of the top 10 orphan 
drugs ranked by potential 340B savings to the 18 hospitals, 
nine are oncology products.    
   
4. The Impact of the Orphan Exclusion will Increase with 
Time 
It is also important to note that the number of drugs with 
orphan designations is growing and forecast to be the next 
generation of blockbusters for the pharmaceutical industry.  
The FDA is currently reviewing a record number of orphan 
drugs under development, increasing the total number of 
drugs potentially ineligible to CAHs at the 340B discount.
25 
 
According to market forecasts, six of the top ten best-selling 
drugs in the US in 2016 will be products with orphan 
designations, including Rituxan, Humira, Avastin, Revlimid, 
Enbrel, and Remicade, representing projected sales of $18.9 
billion.
26   
 
Moreover, once a product is granted orphan designation, it is 
always considered an orphan drug.  Though the market 
exclusivity will eventually expire, the orphan designation will 
not, thereby preventing any future discounts to the CAHs 
under this policy.   
 
Study Limitations 
There are a number of limitations to this study.  First, this 
study reviewed the data for a small subset of geographically-
linked hospitals that participate in a single purchasing 
network, eliminating the ability to generalize the findings to 
the rest of the CAHs in the country.  It was not the objective 
of this research to compute a national estimate for the 
impact of the orphan drug exclusion at this time. Instead, the 
authors sought to provide numbers on the group studied as 
an example of the impact of this policy.  
 
Second, this study did not conduct any multivariate analysis 
to account for variation in the CAH expenditures and 
utilization of orphan drugs.  There are many variables that 
can influence a hospital’s budgetary considerations and a 
complete analysis of them was beyond the scope of this initial 
look at the impact of a policy on a sub-set of hospitals.   
 
Third, the authors contemplated estimating outpatient use by 
applying a proportional outpatient use for drugs that is 
reported for other outpatient services on each CAH’s annual 
Medicare Cost Report, but imputing 100 percent utilization 
for the drugs with orphan designation was deemed more 
reasonable.  Outpatient revenue estimates encompass a wide 
variety of outpatient services available at the hospital, so the 
equal application to utilization of orphan drugs is inadequate, 
a fact confirmed through our informal discussions with a 
number of CAH’s pharmacy directors.  At the same time, 
determining the actual outpatient use for the year by the 
drug would have been overly burdensome to the CAH or to 
FPN.   
 
Fourth, this study only compared savings on purchases, which 
do not equate to the actual savings that would be realized by 
a CAH because of the impact of the lower pharmacy expense 
that would be reported on the hospital’s Medicare Cost 
Report.  This lower cost will ultimately reduce the cost-based 
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reimbursement payments to the CAH by the Medicare 
program and, thus, the actual savings achieved will be 
somewhat less than what is reported here.  However, 
applying the reduced costs to each institution’s Medicare 
reimbursement formula was beyond the scope of this project.  
This point highlights the relationship between the costs of a 
CAH and the Medicare program.  The orphan drug exclusion 
not only impacts the potential 340B savings that can be 
achieved by a CAH, it also creates a missed savings 
opportunity for Medicare. 
 
Finally, this research does not assess the impact of the 
orphan exclusion policy on pharmaceutical manufacturers, as 
it was beyond the scope of the objectives.  
 
Conclusion 
Congress intended for the 340B program to allow covered 
entities to “stretch scarce Federal resources as far as 
possible, reaching more eligible patients and providing more 
comprehensive services.”
27
  By extending the discount 
program to these new entity types, one could reasonably 
assume Congress had the same intention; yet, this study 
highlights how the orphan drug exception diminishes the 
value of participation to the entities.  Given the financial 
impact demonstrated through this research and the current 
economic state, it is reasonable to conclude that the policy of 
excluding high-cost, commonly-used drugs from the 340B 
program should be reconsidered.  Although this study 
reviewed only 18 of the over 1320 CAHs in the country, the 
notion of applying the average per-hospital savings of 
$171,000 to all CAHs does generate critical questions about if 
or how this exclusionary policy should be adopted.  
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TABLE 1: Relationship Between Total Drug Expenditures and Total Spent on Drugs with Orphan Designations by Hospital, 2010 
 
 
 
TABLE 2:  Top 10 Drugs by 340B Savings Potential for the 18 Hospitals, 2010
 
CAH
2010 Total Overall Drug 
Expenditures
2010 Total Orphan Drug 
Expenditures
Percent 
Orphan
2010 Total 
Overall Units
2010 Total 
Orphan Units
Percent 
Orphan
1 $611,722 $252,171 41% 6,224 390 6%
2 $919,136 $445,020 48% 10,088 469 5%
3 $197,448 $14,837 8% 4,737 32 1%
4 $366,601 $122,496 33% 4,427 165 4%
5 $2,244,008 $1,203,799 54% 16,465 1,213 7%
6 $479,551 $268,207 56% 4,337 348 8%
7 $1,472,564 $669,950 45% 8,866 519 6%
8 $3,454,319 $1,531,206 44% 27,946 1,966 7%
9 $967,910 $448,809 46% 8,872 731 8%
10 $578,904 $97,773 17% 13,302 94 1%
11 $2,854,039 $1,233,195 43% 19,628 1,241 6%
12 $665,157 $391,909 59% 4,990 339 7%
13 $408,254 $196,958 48% 3,483 180 5%
14 $1,458,824 $578,311 40% 14,561 709 5%
15 $1,247,412 $630,449 51% 13,568 695 5%
16 $1,773,977 $864,936 49% 13,845 900 7%
17 $1,597,629 $966,611 61% 13,689 1,023 7%
18 $1,188,733 $27,713 2% 14,243 42 0%
Totals $22,486,188 $9,944,348 44% 203,271 11,056 5%
NDC Drug Generic Description
CAH Cost, 
2010
340B Cost, 
2010
Total Savings 
Potential
50242005306 RITUXAN SDV 500MG 50ML RITUXIMAB $1,630,881 $920,535 $710,346
57894003001 REMICADE PWD 100MG IN 20ML VL1 INFLIXIMAB $2,115,176 $1,544,240 $570,936
50242013468 HERCEPTIN MDV 440MG 20ML 1 TRASTUZUMAB $1,085,706 $698,494 $387,212
50242005121 RITUXAN SDV 100MG 10ML RITUXIMAB $703,772 $394,792 $308,980
50242006101 AVASTIN VIAL 400MG 16ML BEVACIZUMAB $864,056 $720,943 $143,113
63020004901 VELCADE VIAL 3.5MG D/SHIP 10ML BORTEZOMIB $312,672 $195,666 $117,006
00002762301 ALIMTA SDV 500MG 50ML PEMETREXED DISODIUM $386,546 $271,891 $114,656
00078038725 ZOMETA CONC VIAL 4MG 5ML ZOLEDRONIC ACID $337,618 $272,597 $65,021
00024059120 ELOXATIN VIAL AQ 100MG 1 OXALIPLATIN $205,067 $144,156 $60,911
63459039120 TREANDA VL 100MG 20ML BENDAMUSTINE HCL $384,884 $328,306 $56,578
$2,534,759Total
